Brief: Graphite Bio Inc - Expects To Incur Estimated Severance And Related Costs Of About $4.9 Million, Which Will Be Recorded Primarily In Q2 Of 2023

LENZ Therapeutics

22/02/2023 22:29

Feb 22 (Reuters) - Graphite Bio Inc  GRPH.O :
    * GRAPHITE BIO INC - EXPECTS TO INCUR ESTIMATED SEVERANCE
AND
RELATED COSTS OF ABOUT $4.9 MILLION, WHICH WILL BE RECORDED
PRIMARILY IN Q2 OF 2023

Further company coverage:  GRPH.O 
 ((Reuters.Briefs@thomsonreuters.com;;))